Aptose clinical data featured in poster presentation at the 2024 ash annual meeting support tuspetinib triple drug therapy for newly diagnosed aml

Tus+ven+aza triplet frontline therapy in newly diagnosed aml patients now enrolling at u.s. sites tus and tus+ven broadly active across aml populations, with favorable safety tus-based therapies are active in flt3 wildtype, representing ~70% of aml patients tus targets ven resistance mechanisms, enabling tus+ven to achieve responses in difficult-to-treat prior-ven failure aml san diego and toronto, dec. 09, 2024 (globe newswire) -- aptose biosciences inc. (“aptose” or the “company”) (nasdaq: apto, tsx: aps), a clinical-stage precision oncology company developing highly differentiated targeted agents to treat hematologic malignancies, today featured a wealth of clinical data for aptose's lead compound tuspetinib (tus) in a poster presentation at the 66th american society of hematology (ash) annual meeting in san diego. poster title: “phase 1 safety and efficacy of tuspetinib plus venetoclax combination therapy in study participants with relapsed or refractory acute myeloid leukemia (aml) support exploration of triplet combination therapy of tuspetinib plus venetoclax and azacitidine for newly diagnosed aml” key findings and messages: tus+ven+aza triplet trial is proceeding in newly diagnosed aml patients tus+ven retains activity in the difficult-to-treat prior-ven aml population tus+ven is active in flt3 wildtype, representing ~70% of aml patients tus+ven is well tolerated and can be safely co-administered tus+ven is active across broad populations of r/r aml combination of tus with ven may avoid ven resistance tus+ven+aza triplet may establish a more effective, mutation agnostic standard of care for chemotherapy ineligible aml patients tuspetinib (tus), being developed by aptose and originally created by hanmi pharmaceutical co., is being advanced as the tus+ven+aza triplet (tuspetinib+venetoclax+azacitidine) for frontline therapy of newly diagnosed aml patients ineligible for intensive chemotherapy.
ASH Ratings Summary
ASH Quant Ranking